Credit Suisse Group cut shares of United Therapeutics (NASDAQ:UTHR) from a neutral rating to an underperform rating in a research note released on Wednesday, MarketBeat Ratings reports.

Several other research analysts also recently weighed in on the company. BidaskClub upgraded United Therapeutics from a hold rating to a buy rating in a research note on Wednesday, July 11th. Barclays cut their price target on United Therapeutics from $105.00 to $95.00 and set an underweight rating for the company in a research note on Thursday, May 3rd. Zacks Investment Research upgraded United Therapeutics from a hold rating to a buy rating and set a $127.00 price target for the company in a research note on Saturday, July 7th. Cowen reiterated a hold rating and set a $110.00 price target on shares of United Therapeutics in a research note on Thursday, August 2nd. Finally, Wedbush increased their price target on United Therapeutics from $234.00 to $253.00 and gave the stock an outperform rating in a research note on Thursday, August 2nd. Two analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $138.86.

United Therapeutics opened at $126.58 on Wednesday, MarketBeat Ratings reports. The company has a quick ratio of 4.35, a current ratio of 4.64 and a debt-to-equity ratio of 0.10. The firm has a market cap of $5.50 billion, a PE ratio of 11.62, a PEG ratio of 29.21 and a beta of 1.28. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, topping the consensus estimate of $2.57 by $1.41. The company had revenue of $444.50 million during the quarter, compared to the consensus estimate of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $4.37 EPS. equities analysts forecast that United Therapeutics will post 14.4 EPS for the current year.

In related news, Director Judy D. Olian sold 600 shares of the stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $112.38, for a total transaction of $67,428.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Raymond Dwek sold 3,240 shares of the stock in a transaction dated Friday, June 29th. The stock was sold at an average price of $113.07, for a total value of $366,346.80. The disclosure for this sale can be found here. Corporate insiders own 8.20% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Legacy Financial Advisors Inc. purchased a new stake in United Therapeutics during the 2nd quarter worth about $107,000. NuWave Investment Management LLC lifted its holdings in United Therapeutics by 13,112.5% during the 1st quarter. NuWave Investment Management LLC now owns 1,057 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 1,049 shares in the last quarter. Sun Life Financial INC purchased a new stake in United Therapeutics during the 2nd quarter worth about $198,000. HL Financial Services LLC lifted its holdings in United Therapeutics by 40.2% during the 1st quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 589 shares in the last quarter. Finally, Trexquant Investment LP purchased a new stake in United Therapeutics during the 1st quarter worth about $266,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Read More: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.